Y-Biologics And Pierre Fabre Form A Strategic Partnership For The Development Of Monoclonal Antibodies.
Y-Biologics, a South Korean Biotech, and Pierre Fabre, a French pharmaceutical group have recently announced their strategic partnership of 3-5 years, in the field of immuno-oncology research.
Both companies plan to optimize their areas of expertise to identify and develop novel therapeutic monoclonal antibodies targeting key immunosuppressive mechanisms activated within solid tumors.
Under the terms of the strategic partnership agreement, Pierre Fabre would have the option to acquire all rights on the antibodies that will be developed under the collaboration. These rights will be subject to payments of discovery fees, milestones, and royalties to Y-Biologics.
Canada Grants Emergency Use Authorization To Eli Lilly’s COVID-19 Antibody.
Eli Lilly’s Neutralizing Antibody Bamlanivibam (LY-CoV555) has recently received authorization from Health Canada as an emergency treatment for the novel COVID-19 virus.
Eli Lilly has received authorization in both Canada and in the United States to use its antibody as an emergency treatment for adult patients with mild to moderate COVID-19.
Eli Lilly aims to manufacture up to 1 million doses of the antibody by the end of this year and will eventually increase supply from the year after.
Celltrion Finishes Enrolling Patients For Phase II Clinical Trial Of COVID-19 Monoclonal Treatment.
Celltrion recently announced that they have finished enrolling 327 patients with mild-to-moderate symptoms of COVID-19 for its global Phase II clinical trial of CT-P59, an anti-COVID-19 monoclonal antibody treatment candidate.
Celltrion expects submission for emergency use authorization (EUA) to the Korean Ministry of Food and Drug Safety (MFDS), once positive results from the global Phase II pivotal trial are obtained.
The global Phase II clinical trial will be a randomized, double-blind, placebo-controlled, and parallel-group trial designed to evaluate the efficacy and safety of CT-P59 in combination with standard of care in patients with COVID-19.
Additionally, Celltrion plans to initiate a global Phase III clinical trial in more than 10 countries to obtain more comprehensive safety and efficacy results of CT-P59.